Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
231 studies found for:    immunoglobuling OR Inmunoglobulina [TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Not yet recruiting IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency
Condition: Asthma
Intervention: Drug: Immune Globulin
2 Completed PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency
Condition: IgG Deficiency
Intervention: Biological: Prevenar13
3 Completed A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura
Conditions: Immune Thrombocytopenic Purpura ( ITP );   HIV Infections
Intervention: Drug: CD4-IgG
4 Completed A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: CD4-IgG
5 Completed A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns
Conditions: HIV Infections;   Pregnancy
Intervention: Drug: CD4-IgG
6 Completed A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex
Condition: HIV Infections
Interventions: Drug: CD4-IgG;   Drug: Zidovudine
7 Terminated GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock
Conditions: Severe Sepsis;   Septic Shock
Intervention: Drug: Immunoglobulin G
8 Completed Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency
Condition: Primary Immune Deficiency
Intervention: Drug: Immunoglobulin G (Ig NextGen 16%)
9 Completed
Has Results
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.
Conditions: 13-valent Pneumococcal Vaccine;   Premature Birth;   Immunization;   Safety
Intervention: Biological: 13-valent pneumococcal conjugate vaccine
10 Completed
Has Results
A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
Condition: Healthy Subjects
Interventions: Biological: 7-pneumococcal conjugate vaccine (7vPnC);   Biological: diphtheria, tetanus, and acellular pertussis vaccine (DTaP);   Biological: DTaP
11 Completed
Has Results
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
Condition: Healthy Subjects
Interventions: Biological: 13-valent pneumococcal conjugate vaccine (13vPnC);   Biological: diphtheria, tetanus, and acellular pertussis vaccine (DTaP);   Biological: 7-valent pneumococcal conjugate vaccine (7vPnC);   Biological: DTaP
12 Terminated IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff
Condition: Clostridium Difficile-associated Diarrhea (CDAD)
Intervention: Drug: intravenous immunoglobulin G (IVIG)
13 Completed IVIG - West Nile Encephalitis: Safety and Efficacy
Condition: West Nile Virus
Interventions: Drug: Omr-lgG-am;   Drug: Polygam® S/D;   Drug: Placebo
14 Completed
Has Results
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
Condition: Pneumococcal Conjugate Vaccine
Intervention: Biological: 13-valent Pneumoccocal Conjugate Vaccine
15 Completed
Has Results
Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
Conditions: Common Variable Immunodeficiency;   Agammaglobulinemia
Intervention: Drug: Vivaglobin
16 Completed
Has Results
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Condition: Vaccines, Pneumococcal Conjugate Vaccine
Interventions: Biological: 13vPnC;   Biological: 23vPS
17 Completed
Has Results
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
Conditions: HIV Infections;   Pneumococcal Infections
Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC);   Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS);   Procedure: Blood draw
18 Completed
Has Results
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
Condition: Pneumococcal Vaccines
Interventions: Biological: 13-valent pneumococcal conjugate vaccine;   Biological: INFANRIX hexa;   Drug: Paracetamol;   Drug: Ibuprofen
19 Completed
Has Results
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Conditions: Primary Immunodeficiency;   Common Variable Hypogammaglobulinemia;   X-linked Hypogammaglobulinemia;   Hypogammaglobulinemia;   Immunodeficiency With Hyper-IgM;   Wiskott-Aldrich Syndrome
Intervention: Biological: Gammaplex (Intravenous immunoglobulin)
20 Completed
Has Results
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
Conditions: HIV Infections;   Pneumococcal Infections
Interventions: Biological: 13-valent pneumococcal conjugate vaccine;   Procedure: Blood draw

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years